<DOC>
	<DOCNO>NCT01405820</DOCNO>
	<brief_summary>The primary objective study explore effect multiple regimen natalizumab disease activity safety participant relapsing-remitting Multiple Sclerosis ( RRMS ) .</brief_summary>
	<brief_title>Exploratory Study Safety , Tolerability Efficacy Multiple Regimens Natalizumab Adult Participants With Relapsing Multiple Sclerosis ( MS )</brief_title>
	<detailed_description>This dose frequency ( route administration ) blind , prospective , randomize , dose-ranging study patient RRMS receive natalizumab least 12 month accord local prescribing guideline . The study explore dose natalizumab subcutaneous intravenous route . Participants randomly assign 1 6 dosing regimen , blind natalizumab dose , route , 60 week treatment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Ability provide write informed consent Subjects childbearing potential must practice effective contraception study A documented diagnosis Relapsing Remitting Multiple Sclerosis ( RRMS ) Free MS relapse 12 month prior randomization Treatment natalizumab minimum 12 month immediately prior randomization . In 12 month prior commence natalizumab , subject must experience minimal level disease activity define 2 documented clinical relapse OR 1 relapse document MRI activity , define presence least 1 Gd enhance lesion MRI , unrelated relapse . Key Known history Human Immunodeficiency Virus ( HIV ) , hepatitis C and/or hepatitis B virus Positive antinatalizumab antibody screen MRI positive Gdenhancing lesion study entry Subjects MRI contraindicate History clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic ( include diabetes ) , urologic , pulmonary , neurologic ( except RRMS ) , dermatologic , psychiatric , renal , major disease History malignant disease , include solid tumor hematologic malignancy ( exception cure basal cell squamous cell carcinoma skin ) History transplantation antirejection therapy History severe allergic anaphylactic reaction know hypersensitivity drug A clinically significant infectious illness within 30 day prior screen progressive multifocal leukoencephalopathy ( PML ) opportunistic infection time Signs symptom suggestive serious infection , base medical history , physical examination laboratory test NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>